An open label multi facilities cooperation randomized control trial to verify postprandial hyperglycemia and hypertriglyceridemia improving effects of DIMS therapy in type 2 diabetes. reducing effect of olmesartan therapy in diabetic nephropathy.
Not Applicable
- Conditions
- Type-2 diabetic patient who has been being hospitalized in our facilities is bedridden and takes liquid diet.
- Registration Number
- JPRN-UMIN000001645
- Lead Sponsor
- Graduate School of Medicine,Tohoku University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Excluding criteria 1)Patient who suffers from serious diseases. 2) Patient who suffers from malignant diseases. 3) Subjects of having received dialysis. 4) Patient who has already taken low carbohydrate liquid diet. 5) Patient that there is allergy in element of liquid diet.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie DIMS therapy's effects on postprandial hyperglycemia and hypertriglyceridemia in type 2 diabetes?
How does DIMS therapy compare to standard-of-care treatments for postprandial hyperglycemia and hypertriglyceridemia in type 2 diabetes with diabetic nephropathy?
Which biomarkers predict response to DIMS therapy and olmesartan in type 2 diabetes patients with diabetic nephropathy?
What adverse events are associated with olmesartan therapy in type 2 diabetes with diabetic nephropathy, and how are they managed?
What combination therapies with angiotensin receptor blockers improve renal outcomes and glucose/lipid metabolism in diabetic nephropathy?